Haemophilia Treatment in Delhi, India

Haemophilia is a rare genetic disorder that impairs the blood's ability to clot, leading to excessive bleeding from even minor injuries. It is characterised by the deficiency or dysfunction of specific clotting factors in the blood. These factors are proteins essential for blood clotting and preventing excessive bleeding. There are different types of haemophilia, each caused by a deficiency in one of the clotting factors. This condition can range from mild to severe, affecting the quality of life and overall health of those affected. Effective management and treatment are crucial for individuals affected by this condition.

At BLK-Max Hospital, Delhi, our dedicated Haematology team provides individualised haemophilia treatment plans - from accurate diagnosis and factor replacement therapy to the latest advances in non-factor therapies and gene therapy evaluation.

Types of Haemophilia Managed at BLK-Max

Haemophilia is classified into several types based on the specific clotting factor that is deficient:

• Haemophilia A (Classic Haemophilia): Caused by a deficiency in clotting factor VIII, it is the most common type of haemophilia, accounting for approximately 80–85% of all cases.
• Haemophilia B (Christmas Disease): Results from a deficiency in clotting factor IX and is also known as Christmas disease. It accounts for approximately 13–15% of haemophilia cases.
• Haemophilia C: Involves a deficiency in clotting factor XI, and is less common, typically causing milder symptoms compared to types A and B. Unlike types A and B, Haemophilia C is not X-linked and can affect both males and females equally.

Haemophilia is also classified by severity based on residual clotting factor activity levels:

• Severe: Factor activity < 1% frequent spontaneous bleeds into joints and muscles.
• Moderate: Factor activity 1–5% bleeding typically after minor trauma.
• Mild: Factor activity 5–40% bleeding mainly with significant injury or surgery.

Symptoms of Haemophilia

Haemophilia manifests through various symptoms related to bleeding and clotting issues:

• Frequent or spontaneous joint bleeding (Haemarthrosis): Bleeding into targeted joints (knees, elbows, ankles) can cause excruciating pain, swelling, and warmth, often occurring without any apparent injury.
• Excessive and deep muscle bruising: Bruises (hematomas) appear more easily and can be larger or more severe than usual, and can compress local nerves.
• Prolonged bleeding from cuts or minor injuries: Minor wounds may take longer to stop bleeding compared to individuals without haemophilia.
• Blood in urine (Haematuria) or stool: Internal bleeding can result in blood being present in urine or stool.
• Swelling and pain in joints or muscles: Accumulated blood in joints or muscles can lead to swelling and significant pain.

Seek Emergency Medical Care Immediately If a Person with Haemophilia Develops:

• Sudden severe headache, confusion, vision changes, or neck stiffness - these may indicate life-threatening intracranial bleeding.
• Severe abdominal pain.
• Inability to move a limb or joint after even a minor fall or injury.
• Any head injury, regardless of whether the person appears well immediately afterwards.

Causes of Haemophilia

The causes of haemophilia are primarily genetic:

• Genetic mutations: Haemophilia is caused by mutations in the genes responsible for producing clotting factors, leading to their deficiency or dysfunction. Specifically, Haemophilia A involves mutations in the F8 gene (Factor VIII) and Haemophilia B in the F9 gene (Factor IX).
• Inheritance of the defective gene: Haemophilia is inherited in an X-linked recessive pattern, meaning it is passed from parent to child through the X chromosome. Approximately one-third of all haemophilia cases, however, arise from new (de novo) mutations with no prior family history meaning a negative family history does not exclude the diagnosis.
• Rare cases: In some instances, haemophilia can develop due to immune system disorders that interfere with blood clotting factors. This is called Acquired Haemophilia A and can affect adults with no prior history of bleeding disorders, often associated with autoimmune conditions or the postpartum period.

Diagnosing Haemophilia at BLK-Max Hospital, Delhi

Diagnosing haemophilia involves several steps to accurately assess the condition. At BLK-Max Hospital, most confirmatory diagnostic tests are conducted in-house, enabling rapid and accurate results.

1. Medical History and Family History Assessment

Reviewing the patient’s and their family’s medical history helps identify potential genetic factors and symptoms.

2. Blood tests

Specific tests measure the levels of clotting factors in the blood to determine any deficiencies. Initial screening includes Activated Partial Thromboplastin Time (aPTT) typically prolonged in Haemophilia A and B and Prothrombin Time (PT), which is usually normal in haemophilia and helps exclude other coagulopathies. Definitive diagnosis is established by directly measuring Factor VIII activity (Haemophilia A) or Factor IX activity (Haemophilia B) through specific clotting factor assays.

3. Genetic testing

Genetic tests can pinpoint the exact mutations causing haemophilia. Molecular testing of the F8 or F9 gene is also used for carrier detection in female relatives and for prenatal or preimplantation genetic diagnosis in families at risk.

4. Inhibitor Testing (Bethesda Assay)

For patients already receiving factor replacement therapy, inhibitor testing detects neutralising antibodies against clotting factors. Inhibitor status must be routinely screened as it fundamentally changes the treatment approach.

5. Physical examination

A thorough physical exam helps evaluate bleeding symptoms and any joint damage.

Treatment Options for Haemophilia at BLK-Max Hospital, Delhi

Treatment aims to manage symptoms and prevent complications. At BLK-Max, our haematologists design individualised treatment plans based on haemophilia type, severity, inhibitor status, age, and access requirements. The primary goal of modern haemophilia care is to prevent bleeds before they occur.

1. Factor Replacement Therapy with Clotting Factor Concentrates

Involves infusing clotting factor concentrates to replace the deficient factors in the blood. Factor concentrates are available as recombinant products (no human plasma) and virally inactivated plasma-derived products. Therapy may be given as:

• Prophylaxis (preventive): Regular scheduled infusions to maintain factor levels above the bleed-prevention threshold. Prophylaxis is the internationally recommended standard of care for severe haemophilia and has been shown in landmark clinical trials to substantially reduce annual bleed rates and prevent joint damage.
• On-demand: Factor infusions given to treat an active bleed as it occurs - appropriate for mild haemophilia.
• Extended Half-Life (EHL) Factor Concentrates: Newer recombinant products engineered for a longer duration of action, requiring less frequent infusions and improving treatment adherence.

2. Desmopressin (DDAVP)

Used to stimulate the release of stored clotting factors, mainly for mild cases of haemophilia A. It is not effective in Haemophilia B.

3. Non-Factor-Based Therapies

A new generation of haemophilia treatments that rebalance the coagulation system without replacing the missing clotting factor. These agents are administered subcutaneously (under the skin) and can be self-administered at home:

• Emicizumab (Hemlibra): A bispecific antibody mimicking Factor VIII function, approved for Haemophilia A with and without inhibitors across all age groups. Clinical trials demonstrated up to an 87% reduction in annual bleed rates compared to no prophylaxis.
• Fitusiran: An RNA interference (RNAi)-based therapy administered as a monthly subcutaneous injection, effective in both Haemophilia A and B with or without inhibitors.

4. Gene Therapy

A newer approach aiming to correct the defective gene responsible for haemophilia, potentially offering long-term relief. Two gene therapies have now received regulatory approval:

• Etranacogene dezaparvovec (Hemgenix) for Haemophilia B: Approved by the US FDA in 2022 as the world's first approved haemophilia gene therapy. Clinical data showed 94% of participants achieved independence from routine Factor IX prophylaxis at 18 months post-infusion.
• Valoctocogene roxaparvovec (Roctavian) for Haemophilia A: Received FDA and EMA approval in 2023, demonstrating significant sustained increases in Factor VIII activity and reductions in bleeding episodes.

5. Immune Tolerance Induction Therapy

For patients who develop inhibitors against clotting factor treatments, this therapy aims to reduce or eliminate the immune response. Inhibitors develop in approximately 20–30% of patients with severe Haemophilia A. ITI achieves inhibitor eradication in approximately 60–80% of eligible patients.

Why Choose BLK-Max Hospital for Haemophilia Treatment in Delhi?

BLK-Max Hospital is one of North India's leading super-specialty hospitals with a dedicated Haematology and BMT programme. Our haemophilia care is defined by:

• Subspecialty haematologists experienced in bleeding disorders, inhibitor haemophilia, and gene therapy evaluation.
• A Multidisciplinary Team (MDT) including haematologists, orthopaedic surgeons, physiotherapists, genetic counsellors, and psychosocial support - coordinated under one roof.
• Comprehensive in-house diagnostics including clotting factor assays, Bethesda inhibitor testing, and molecular genetic testing.
• Access to extended half-life factor concentrates and non-factor therapies such as emicizumab.
• Dedicated protocols for paediatric and adult patients across all stages of the haemophilia journey.

Complications of Haemophilia

Complications from haemophilia can significantly impact health and quality of life. With consistent modern treatment, most complications are preventable:

• Chronic joint damage and arthritis: Repeated bleeding into joints can lead to long-term damage and arthritis. This is called haemophilic arthropathy and is the most common long-term complication of severe haemophilia. Early prophylaxis is the most effective strategy to prevent it.
• Intracranial bleeding: Bleeding in the brain can cause serious neurological issues and complications. This is the most life-threatening complication of haemophilia and constitutes a medical emergency requiring immediate factor replacement.
• Formation of inhibitors against clotting factor treatments: Some patients may develop antibodies that inhibit the effectiveness of clotting factor therapies.
• Bloodborne virus transmission: This was a significant risk before the 1990s. Modern recombinant and virally inactivated plasma-derived factor concentrates carry no known risk of bloodborne virus transmission. Patients and families can be fully reassured on this point.
• Emotional and psychological challenges: Chronic illness and frequent treatments can lead to emotional and psychological stress. BLK-Max's care model includes access to psychosocial support as part of the standard haemophilia care pathway.

Recovery and Monitoring

Recovery from an acute bleed depends on its location and severity:

• Joint bleeds: Most resolve within 24–72 hours with prompt factor replacement and RICE (Rest, Ice, Compression, Elevation). Physiotherapy is important after significant joint bleeds to restore mobility.
• Muscle haematomas: May take days to weeks to resolve; monitoring for compartment syndrome is essential.

Ongoing monitoring for patients on treatment:

• Clotting factor levels and inhibitor screening: every 6–12 months
• Annual joint assessment: clinical examination and, where indicated, ultrasound or MRI
• Dental review every 6 months: all dental procedures require pre-procedural factor cover
• Hepatitis A and B antibody titres: annually

Regular physical activity is actively encouraged - swimming, cycling, and walking are beneficial for joint health. High-contact sports are generally discouraged in severe haemophilia. Our team provides personalised activity guidance.

Risk Factors for Haemophilia

Several factors increase the likelihood of developing haemophilia:

• Family history of haemophilia or bleeding disorders: A family history of haemophilia raises the risk of inheriting the condition. However, approximately one-third of cases arise from de novo mutations with no prior family history.
• Inheritance of the defective gene from parents: Genetic inheritance plays a crucial role in the development of haemophilia.
• Gender: Haemophilia predominantly affects males due to its X-linked inheritance pattern. Female carriers can also have reduced factor activity levels and may experience symptoms - particularly heavy menstrual bleeding - which is frequently underdiagnosed.
• History of spontaneous bleeding or excessive bruising: A history of unexplained bleeding or bruising may indicate haemophilia.

Prevention of Haemophilia Complications

Preventive measures are essential to manage haemophilia effectively:

• Regular treatment: Ongoing treatment helps maintain adequate clotting factor levels and prevent bleeding episodes. Primary prophylaxis, started early in childhood before the first joint bleed, is the most effective strategy to prevent haemophilic arthropathy and long-term disability.
• Avoidance of activities with a high risk of injury or trauma: Minimising activities that could cause injury helps reduce bleeding risks.
• Prompt treatment: Immediate treatment for bleeding episodes helps prevent complications and further damage. The "treat early, treat effectively" principle is central - initiating factor replacement at the first sign of a bleed minimises joint damage.
• Genetic counselling: Genetic counselling can provide information and support for families with a history of the condition. BLK-Max Hospital offers genetic counselling as part of our comprehensive haemophilia care programme.

Conclusion

Understanding haemophilia and its management is crucial for improving the quality of life for those affected. Early detection, accurate diagnosis, and effective treatment are key to managing this condition. Advances in medical treatments and therapies offer hope for better management and potential future cures for haemophilia. Today, with modern prophylactic therapy, non-factor biologics, and gene therapy now approved, individuals with haemophilia can expect near-normal life expectancy and substantially improved quality of life.

At BLK-Max Hospital, our mission is to make expert haemophilia care accessible, transparent, and compassionate - at every stage of your journey.

Frequently Asked Question

1. How do I book a haemophilia consultation at BLK-Max Hospital in Delhi?

You can book a consultation with BLK-Max Hospital's Haematology team. Same-day or next-day appointments are available for urgent cases.

2. What documents should I bring to my first haemophilia appointment?

Please bring: previous blood test results (clotting factor assays, aPTT/PT reports), a list of current medications, any prior factor replacement prescriptions or infusion records, genetic test results if available, and prior discharge summaries related to bleeding episodes. A GP referral is helpful but not mandatory.

3. What is the approximate cost of haemophilia treatment in Delhi?

Costs depend on the treatment type (on-demand vs. prophylaxis), the factor concentrate prescribed, body weight, and infusion frequency. Recombinant factor products are typically priced higher than plasma-derived options. A personalised estimate can be provided by BLK-Max's billing department after your initial haematology consultation.

4. Can I have elective surgery if I have haemophilia?

Yes with specialist perioperative planning. Our haematology and surgical teams develop a comprehensive pre-, intra-, and postoperative factor replacement protocol to ensure safe surgery. Surgery should never be performed at a facility without immediate access to factor concentrates and haematology support.

5. What is a haemophilia inhibitor and how is it treated?

An inhibitor is an antibody that neutralises infused clotting factor, making standard replacement therapy ineffective. It develops in approximately 20–30% of patients with severe Haemophilia A. Treatment options include bypass therapy, emicizumab (unaffected by Factor VIII inhibitors), or Immune Tolerance Induction (ITI) to eliminate the inhibitor over time.

6. What are the long-term outcomes for someone with haemophilia receiving modern treatment?

With consistent modern prophylaxis factor-based or non-factor-based individuals with haemophilia can expect near-normal life expectancy and significantly improved quality of life compared to previous generations. Early prophylaxis in childhood substantially reduces joint damage and disability over a lifetime.

7. How does prenatal testing for haemophilia work?

Female carriers have several options: Chorionic Villus Sampling (CVS) from ~11 weeks or amniocentesis from ~15 weeks can identify whether the foetus carries the haemophilia gene. Preimplantation Genetic Testing (PGT) with IVF allows selection of unaffected embryos before implantation. BLK-Max offers genetic counselling to guide families through these decisions.

8. Can haemophilia be permanently treated with a single infusion?

Gene therapy is the closest current approximation. A single gene therapy infusion can enable the patient's own liver to produce a clotting factor with 94% of Haemophilia B participants in the pivotal HOPE-B trial achieving independence from routine prophylaxis at 18 months. Long-term durability beyond 5–7 years is still being studied, and eligibility criteria currently apply. Our team can assess your suitability.

9. How does Haemophilia affect the body?

Haemophilia impairs blood clotting, leading to prolonged bleeding from injuries, spontaneous bleeding, and potential joint damage due to repeated bleeding.

10. How common is Haemophilia?

Haemophilia is relatively rare, with haemophilia A being the most common type. It affects approximately 1 in 5,000 male births.

11. Can Haemophilia be cured?

Currently, there is no complete cure for haemophilia, but treatments like factor replacement therapy and gene therapy offer effective management and potential long-term relief.

12. How is Haemophilia inherited?

Haemophilia is inherited in an X-linked recessive pattern, meaning it is passed from mother to child through the X chromosome. Males are typically affected, while females are carriers.

13. Can women have Haemophilia?

Women can have haemophilia, but it is rare. They are usually carriers of the gene and may have mild symptoms if they inherit two defective X chromosomes.

14. What is the life expectancy for someone with Haemophilia?

With proper treatment and management, individuals with haemophilia can have a normal life expectancy. Early diagnosis and effective care are crucial.

15. Can Haemophilia be prevented?

Haemophilia cannot be prevented due to its genetic nature, but complications can be managed and minimised through regular treatment and preventive care.

16. How does Haemophilia impact daily life?

Haemophilia can affect daily life by limiting physical activities, requiring frequent medical treatments, and potentially causing psychological stress due to the chronic nature of the condition.